Equine Protozoal Myeloencephalitis (EPM) is a debilitating neurological disease that affects horses. Caused by the protozoan parasites Sarcocystis neurona and Neospora hughesi, EPM can lead to a variety of symptoms, including ataxia, weakness, muscle wasting, and even paralysis. Treating EPM has historically been challenging, but in recent years, a drug called toltrazuril has shown promising results in combating this devastating condition. In this blog, we will delve into the details of toltrazuril and its effectiveness in treating EPM in horses.
Understanding EPM: Before we explore toltrazuril's role in treating EPM, let's briefly understand the disease itself. EPM is primarily contracted through horses consuming feed or water contaminated with opossum feces, which contain the infective stages of S. neurona and N. hughesi. Once inside the horse's body, these parasites migrate to the central nervous system, causing inflammation and damage to the spinal cord and brain.
Toltrazuril: An Overview: Toltrazuril is an antiprotozoal drug that has gained recognition as a potential treatment option for EPM. Originally developed for use in poultry and swine, it has been successfully repurposed for use in horses. This drug is a member of the triazinone class of compounds and works by inhibiting the parasite's ability to reproduce and spread within the horse's body.
Efficacy of Toltrazuril in EPM Treatment: Several studies have highlighted the effectiveness of toltrazuril in combating EPM in horses. One study conducted at the University of Kentucky demonstrated that toltrazuril was capable of reducing parasite numbers and improving clinical signs in horses with experimentally induced EPM.
In a field study carried out on naturally infected horses, toltrazuril treatment showed a significant improvement in clinical signs, such as improved gait and muscle tone, reduced ataxia, and increased appetite. Moreover, these improvements were observed within a few weeks of starting the treatment, leading to enhanced quality of life for affected horses.
Administration and Dosage: Toltrazuril is available in oral suspension form and paste form, making it easy to administer to horses. The recommended dosage and duration of treatment may vary depending on the severity of the infection, the horse's size, and the veterinarian's recommendation. It is crucial to follow the prescribed dosage and complete the entire course of treatment to ensure the eradication of the parasites and prevent relapses.
Safety and Side Effects: Toltrazuril has generally been well-tolerated by horses, with few reported side effects. However, as with any medication, individual sensitivities can occur. Potential side effects may include temporary diarrhea, mild anorexia, and transient increases in liver enzyme levels. If any adverse effects are observed, it is important to consult with a veterinarian promptly.
Conclusion: EPM is a challenging condition that can significantly impact a horse's well-being. Fortunately, the emergence of toltrazuril as a treatment option brings hope to owners and veterinarians alike. Its antiprotozoal properties and proven efficacy against S. neurona and N. hughesi make it a valuable tool in combating EPM. However, it is crucial to remember that timely diagnosis, proper treatment, and follow-up care are essential components of managing this disease effectively.
If you suspect your horse may be suffering from EPM or any other health condition, it is always recommended to consult with a qualified veterinarian for an accurate diagnosis and appropriate treatment plan. Together, we can strive to improve the lives of horses affected by EPM and ensure their well-being and vitality.
CLICK HERE to order Toltrazuril